Cardiovascular Business October 4, 2024
New UCLA-led research reinforces the important role guideline-directed medical therapy (GDMT) can play in reducing mortality rates in patients with heart failure with reduced ejection fraction (HFrEF). HFrEF affects about 29 million people worldwide, according to the study’s authors.
The analysis, published in JAMA Cardiology, found that many patients eligible to be given life-saving medical therapy do not receive it, demonstrating the challenge in implementing global guidelines.[1]
Researchers identified 8.2 million patients who qualify, but do not receive, beta blocker treatment. Large numbers of patients were also identified who are missing out on angiotensin receptor neprilysin inhibitors (20.4 million), mineralocorticoid receptor antagonists (12.2 million) and SGLT2 inhibitors (21.2 million).
“These guidelines are being significantly underutilized in clinical settings globally and...
Today's Sponsors
Today's Sponsor